Entasis Scores! The FDA's anti-infectives advisory board unanimously recommended approval of Entasis sulbactam-durlobactam for the treatment of hospital and ventilator-acquired pneumonia, caused by ...
Entasis Therapeutics steered its lead antibiotic candidate through late-stage clinical development with help from Innoviva, which has steadily invested in the company over the past two years and now ...
WALTHAM, Mass.--(BUSINESS WIRE)--Entasis Therapeutics, a company leveraging its expertise and a unique pathogen-targeted approach to develop and advance novel antibacterials, debuted today with a ...
Entasis Therapeutics has filed to raise up to $86 million through an IPO. The AstraZeneca spinout is seeking the money to fund a phase 3 trial of a drug to overcome bacterial resistance to ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. WASHINGTON — Entasis Therapeutics announced at the World ...
WALTHAM, Mass., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results